Biotech Decision Makers
A verified directory of 318 people who approve R&D and lab spend — with the budget they own, the procurement path, and the validation evidence needed.
Last verified
- 318
- Biotech decision makers
- 75
- Can raise a PO alone
- 38%
- Inside a planning window
- 63%
- Require GxP evidence
Verified in the last 30 days
Under the threshold, no MSA needed
Next-year budget being scoped now
Validation pack before a trial starts
Free preview
6 of 318 profiles
Names, roles, companies and live signals are public. Verified emails and LinkedIn URLs stay masked until you sign in.
- 01
Wilhelmina Osaretin-Culpepper
Executive Director, Discovery Informatics · Marchmont Pharma
Groton, CT
Scoping the FY27 informatics budget now; three categories still unassigned.
- Large pharma
- Data and informatics
- MSA required
- Planning window
- w•••••@marchmontpharma.com Locked
- 02
Nikolaj Abimbola-Trentham
VP of Clinical Operations · Fernhollow Therapeutics
Seaport, Boston
Opening 18 trial sites this autumn; replacing an eTMF that failed a sponsor audit.
- Clinical-stage biotech
- Clinical operations
- Competitive RFP
- Replacing vendor
- n•••••@fernhollowtx.com Locked
- linkedin.com/in/•••••• Locked
- 03
Consuelo Iheanacho-Radcliffe
Head of Quality Assurance · Bramwell CDMO
Research Triangle Park, NC
Will not evaluate anything without a Part 11 validation pack; asks for it on the first call.
- CRO or CDMO
- Regulatory and quality
- Preferred-vendor list
- Validation gate
- c•••••@bramwellcdmo.com Locked
- linkedin.com/in/•••••• Locked
- 04
Yusuf Landsberg-Ekanem
Core Facility Director · Ravensmoor Institute
Hyde Park, Chicago
Grant-funded instrument refresh approved; purchasing decisions made by him alone.
- Academic core
- Discovery and research
- Direct PO
- Funded refresh
- y•••••@ravensmoorinstitute.org Locked
- linkedin.com/in/•••••• Locked
- 05
Delphine Mutumbo-Ashgrove
Senior Director, CMC · Ravelston Biologics
Torrey Pines, San Diego
Tech transfer to a second manufacturing site starts in October; tooling decisions due in weeks.
- Mid-cap biopharma
- Manufacturing and CMC
- MSA required
- Deadline driven
- d•••••@ravelstonbio.com Locked
- linkedin.com/in/•••••• Locked
- 06
Tarquin Oyelowo-Bergstrand
Director of Research Operations · Kelsterne Bio
Mission Bay, San Francisco
Signs anything under a set threshold without procurement; uses it to run paid pilots quarterly.
- Clinical-stage biotech
- Discovery and research
- Direct PO
- Runs pilots
- t•••••@kelsternebio.com Locked
- linkedin.com/in/•••••• Locked
Unlock the full Biotech Decision Makers list
The other 312 profiles are in Articuler. A free account runs 3 directory matches a day — every match returns full profiles with verified emails and LinkedIn URLs. Upgrade for unlimited matches, filtering and export.
Sign in to unlock the full listFree account · No credit card · Takes about 30 seconds
Opens Articuler search for “Biotech Decision Makers”
Frequently asked questions
- Why does the procurement path matter more than the job title?
- Because it sets the calendar. 104 of these buyers cannot start any work at all until a master service agreement is executed, which is a legal negotiation measured in months and happens before anyone evaluates your product. The 75 who can raise a purchase order under a threshold can be running a paid trial in a fortnight. Same seniority, ten times the difference in time to first revenue.
- What is a validation pack and when do I need one?
- It is the documented evidence that a system does what it claims under a regulated process — installation and operational qualification, audit trails, 21 CFR Part 11 controls where electronic records are involved. 63% of this list will not begin a GxP-scoped evaluation without it. If your product touches anything downstream of a regulatory filing, assemble it before the first call rather than after the first objection.
- Are academic core facilities worth selling to?
- 36 are listed, and they are the most underrated entry point in the sector. Budgets are small and grant-tied, but a core facility manager influences what every lab in the institution uses, and the evaluation is technical rather than procedural. Companies that start there frequently end up inside the pharma groups those researchers move to.
- How is a CRO buyer different from a biotech buyer?
- A CRO buys on behalf of its own clients, so the 52 here are evaluating whether a tool makes their delivery cheaper or faster across many programmes at once. The economics are unit-cost driven and the contracts are larger and slower. A clinical-stage biotech buyer, by contrast, is solving one programme's problem and will pay a premium to solve it this quarter.
- Does a preferred-vendor list ever open up?
- It does, usually at renewal or after a category owner changes, which is why 78 buyers are tracked with that status rather than written off. Getting added mid-cycle is possible but requires an internal sponsor willing to justify an exception. The practical strategy is to know the renewal date, which is the kind of timing the record behind the gate carries.
- What does 'inside a planning window' mean for these buyers?
- 38% are scoping next fiscal year's budget now. In R&D organisations the money is committed to programmes long before it is spent, so a vendor who appears during scoping gets a line item and a vendor who appears in month three of the year gets told to come back. Timing beats messaging in this segment more than in almost any other.